BioSpace News Archive

Workplace conflict is bound to happen throughout your career. Learn how to take advantage of moments of discord to identify opportunities for growth, learning, and collaboration.

Prior to being acquired by Medtronic, the two companies were involved in what the DOJ called kickback schemes to encourage unauthorized use of a medical device.

Georgia-based MiMedx has been dealing with continued fallout from questions over its earnings and sales practices.

Researchers have hunted for years to find a commonality across all cancers, a so-called “silver bullet” that ties them all together. Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology have identified a nano-scaled DNA signature that seems to be common to all cancers. This has the potential to be used as an early cancer detection test, what is often called a liquid biopsy.

The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.

In July 2017, Bayer launched a three-year, Phase III ASTEROID clinical trial of vilaprisan in patients with symptomatic uterine fibroids, with the intention of recruiting more than 3,600 patients in 900 sites in 40 countries.

While Xarelto failed to show statistical significance, Janssen said there was a clinically meaningful 60 percent reduction of VTE events compared to placebo during times of treatment.

Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.

The capabilities of medical science continue to astound. Nearly one year ago, a baby girl was born using a uterus, or womb, transplanted from a deceased woman.

The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.